A Hong Kong SFC official warned that the new local stablecoin framework has fueled fraud risks, and urged investors to remain cautious amid hype-driven speculation. A Hong Kong Securities and Futures Commission (SFC) official warned that the introduction of the new local stablecoin regulatory framework has increased the risk of fraud. According to an Aug. 18 report by Chinese financial news outlet Zhitongcaijing, Ye Zhiheng, executive director of the intermediaries division at the SFC, said that fraud risks have increased with the recent introduction of stablecoin regulations. He urged investors to exercise caution and avoid making irrational investment decisions driven by market hype or price momentum. Ye’s remarks followed stablecoin companies operating in Hong Kong posting double-digit losses on Aug. 1, just after the new stablecoin regulation came into force. Analysts at the time described the sell-off as a healthy correction, as the requirements for stablecoin issuers proved to be more stringent than exp...
Bitcoin no longer has promising odds of a breakout in coming days as opinions differ on what caused the BTC price dip and what will happen next. Bitcoin (BTC) started a new week with a fresh sell-off, and traders are split over where it will head next. BTC price action has dipped $10,000 since its latest all-time high just days ago, leading to comparisons with the 2021 top. Order-book manipulation may be to blame, analysis argued; a large entity may be “buying the dip.” Read more
Romania's Competition Council is looking into a transaction through which Vinci Energies S.R.L. intends to acquire the companies Energobit S.A., ELM Electromontaj Cluj S.A. and Energobit Control Systems S.R.L.
Romania's Competition Council is assessing the transaction through which RZ International Beteiligungs GMBH, Austria, intends to acquire the companies Thermonet Beteiligungs GMBH, Austria, and Thermonet SRL.
Romania's Competition Council is analyzing the transaction through which Hartmann Packaging A/S plans to acquire Dentas Romania SRL.
Drug manufacturer Biofarm (BIO.RO) posted sales revenue of RON162.9 million in the first half of 2025, up 15% from the same period in 2024, while net profit increased by 16% to RON48.8 million, according to the financial report published on the Bucharest Stock Exchange.